CERS - Cerus Corp Stock Price, Fair Value and News

1.88USD0.00 (0.00%)Delayed as of 09 May 2024, 02:02 pm ET

Market Summary

USD1.880.00

Delayedas of 09 May 2024, 02:02 pm

0.00%

CERS Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

CERS Stock Price

View Fullscreen

CERS RSI Chart

CERS Valuation

Market Cap

347.6M

Price/Earnings (Trailing)

-11.01

Price/Sales (Trailing)

1.86

EV/EBITDA

-16.46

Price/Free Cashflow

-9.42

CERS Price/Sales (Trailing)

CERS Profitability

EBT Margin

-16.80%

Return on Equity

-62.95%

Return on Assets

-16.69%

Free Cashflow Yield

-10.61%

CERS Fundamentals

CERS Revenue

Revenue (TTM)

186.8M

CERS Earnings

Earnings (TTM)

-31.6M

Earnings Growth (Yr)

38.06%

Earnings Growth (Qtr)

-651.59%

Breaking Down CERS Revenue

52 Week Range

1.403.08

(Low)(High)

Last 7 days

8.7%

Last 30 days

-1.6%

Last 90 days

-18.7%

Trailing 12 Months

-13.4%

How does CERS drawdown profile look like?

CERS Financial Health

Current Ratio

2.41

CERS Investor Care

Shares Dilution (1Y)

2.40%

Diluted EPS (TTM)

-0.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	187.9M	187.6M	187.2M	186.8M
2022	0	0	0	188.3M
2021	116.2M	120.6M	126.5M	159.5M
2020	95.0M	96.7M	98.9M	114.2M
2019	0	76.3M	79.0M	135.9M
2018	50.1M	48.3M	44.8M	79.7M
2017	36.6M	36.8M	37.5M	43.6M
2016	34.2M	34.6M	36.7M	37.2M
2015	36.2M	36.5M	34.2M	34.2M
2014	37.8M	36.2M	36.1M	36.4M
2013	37.7M	38.7M	41.0M	39.7M
2012	33.1M	35.6M	36.1M	36.7M
2011	22.1M	23.0M	25.7M	30.6M
2010	0	19.2M	20.4M	21.7M
2009	0	0	0	18.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cerus Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	corash laurence m	sold	-28,352	1.9744	-14,360	chief scientific officer
Mar 14, 2024	greenman william mariner	sold	-128,195	2.0153	-63,611	president and ceo
Mar 14, 2024	jayaraman vivek k	sold	-52,902	1.9744	-26,794	chief operating officer
Mar 14, 2024	benjamin richard j	sold	-35,021	1.9744	-17,738	chief medical officer
Mar 14, 2024	jensen chrystal	sold	-35,191	1.9744	-17,824	chief legal officer
Mar 14, 2024	green kevin dennis	sold	-42,443	1.9744	-21,497	chief financial officer
Mar 13, 2024	green kevin dennis	sold	-42,438	2.0153	-21,058	chief financial officer
Mar 13, 2024	greenman william mariner	sold	-128,182	2.057	-62,315	president and ceo
Mar 13, 2024	corash laurence m	sold	-28,935	2.057	-14,067	chief scientific officer
Mar 13, 2024	moore carol	sold	-41,552	2.01527	-20,619	svp reg. & quality

Which funds bought or sold CERS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-0.31	-13,000	85,000	-%
May 07, 2024	SEI INVESTMENTS CO	new	-	65,706	65,706	-%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-90.52	-1,036,650	93,812	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-94.39	-388,000	20,000	-%
May 06, 2024	Quantbot Technologies LP	sold off	-100	-31,884	-	-%
May 03, 2024	EASTERLY INVESTMENT PARTNERS LLC	new	-	405,001	405,001	0.03%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-14.68	-549,000	1,619,000	0.13%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	reduced	-2.26	-7,376	43,572	-%
May 03, 2024	PrairieView Partners, LLC	unchanged	-	1,000	1,000	-%
May 02, 2024	Nikko Asset Management Americas, Inc.	added	2.41	-1,775,720	14,571,300	0.14%

Are Funds Buying or Selling CERS?

Are funds buying CERS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CERS

No. of Funds

Unveiling Cerus Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	baker bros. advisors lp	10.7%	19,477,339	SC 13G/A
Feb 13, 2024	vanguard group inc	5.45%	9,870,671	SC 13G/A
Jan 29, 2024	ark investment management llc	11.54%	20,914,326	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	13,728,396	SC 13G/A
Nov 13, 2023	baker bros. advisors lp	10.5%	19,082,012	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	9.1%	16,067,558	SC 13G/A
Feb 10, 2023	ark investment management llc	10.11%	17,943,131	SC 13G/A
Feb 10, 2023	ark investment management llc	8.94%	15,863,384	SC 13G/A
Feb 10, 2023	nikko asset management americas, inc.	4.04%	7,171,280	SC 13G/A
Feb 09, 2023	vanguard group inc	6.14%	10,900,422	SC 13G/A

Recent SEC filings of Cerus Corp

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 19, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to Cerus Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	422.2M	169.3M	11.74%	12.93%	-5.49	2.49	7.49%	-244.90%
ANGO	235.9M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	46.8M	52.3M	-10.27%	-60.90%	-2.5	0.89	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.87	5.77%	8.23%

Cerus Corp News

Latest updates

Cerus Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-	-	-	-	-	-	112,524,000	18,549,000	16,161,000	12,284,000	79,506,000	12,654,000	11,798,000	10,291,000	64,168,000	10,436,000	10,098,000	51,195,000	7,257,000	7,700,000	13,564,000	16,240,000
Operating Expenses	-8.6%	31,557,000	34,538,000	41,853,000	38,935,000	41,774,000	37,575,000	35,645,000	36,841,000	34,918,000	35,752,000	32,220,000	31,730,000	31,723,000	33,602,000	32,221,000	31,157,000	27,254,000	24,789,000	24,318,000	-	-
S&GA Expenses	6.9%	17,269,000	16,155,000	20,541,000	21,551,000	23,160,000	22,003,000	20,357,000	19,758,000	19,170,000	18,691,000	16,299,000	16,112,000	15,913,000	17,164,000	16,140,000	16,740,000	14,833,000	13,964,000	14,437,000	-	-
EBITDA Margin	32.2%	-0.14	-0.21	-0.22	-0.20	-0.18	-0.29	-0.41	-0.44	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.7%	2,229,000	2,364,000	2,181,000	1,612,000	1,697,000	1,334,000	1,279,000	1,338,000	972,000	952,000	930,000	929,000	935,000	960,000	1,031,000	1,150,000	1,082,000	1,053,000	958,000	-	-
Income Taxes	-7.7%	72,000	78,000	98,000	77,000	267,000	71,000	73,000	77,000	98,000	92,000	68,000	67,000	57,000	82,000	60,000	61,000	60,000	56,000	59,000	-	-
Earnings Before Taxes	81.7%	-1,317,000	-7,208,000	-13,233,000	-15,564,000	-13,358,000	-9,050,000	-12,364,000	-15,284,000	-17,359,000	-14,289,000	-14,071,000	-14,804,000	-16,409,000	-16,841,000	-17,907,000	-17,501,000	-16,145,000	-14,136,000	-13,223,000	-	-
EBT Margin	24.2%	-0.20	-0.26	-0.27	-0.24	-0.22	-0.34	-0.47	-0.51	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	82.3%	-1,289,000	-7,267,000	-13,331,000	-15,641,000	-13,621,000	-9,119,000	-12,437,000	-15,361,000	-17,457,000	-14,381,000	-14,139,000	-14,871,000	-16,466,000	-16,923,000	-17,967,000	-17,562,000	-16,205,000	-14,192,000	-13,282,000	-	-
Net Income Margin	24.6%	-0.20	-0.27	-0.27	-0.25	-0.23	-0.34	-0.47	-0.51	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-15.6%	-15,177,000	-13,124,000	-9,440,000	-10,024,000	-2,991,000	-1,686,000	-6,803,000	-8,695,000	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.4%	189	198	206	199	209	218	215	216	222	237	219	223	221	221	213	215	215	166	164	175	176
Current Assets	-4.3%	138	144	151	151	162	170	165	165	173	187	178	186	181	183	177	179	178	128	126	136	135
Cash Equivalents	90.9%	22.00	12.00	17.00	21.00	28.00	36.00	31.00	34.00	40.00	51.00	81.00	61.00	60.00	39.00	31.00	37.00	36.00	37.00	27.00	26.00	32.00
Inventory	0.0%	40.00	40.00	43.00	41.00	37.00	29.00	28.00	28.00	29.00	27.00	29.00	31.00	24.00	23.00	19.00	18.00	22.00	19.00	21.00	17.00	16.00
Net PPE	-6.3%	8.00	9.00	9.00	10.00	11.00	11.00	11.00	11.00	12.00	12.00	13.00	13.00	13.00	14.00	14.00	15.00	15.00	15.00	15.00	15.00	16.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-3.7%	139	144	157	147	150	150	141	140	141	152	138	139	128	118	104	101	103	108	104	109	106
Current Liabilities	-15.2%	57.00	68.00	80.00	75.00	78.00	117	95.00	79.00	67.00	79.00	65.00	66.00	55.00	60.00	46.00	43.00	45.00	50.00	46.00	51.00	48.00
Shareholder's Equity	-4.7%	50.00	53.00	48.00	52.00	60.00	68.00	74.00	77.00	80.00	86.00	81.00	84.00	93.00	104	109	115	112	57.00	61.00	66.00	70.00
Retained Earnings	-0.9%	-1,054	-1,044	-1,043	-1,036	-1,022	-1,007	-993	-985	-976	-964	-955	-942	-927	-909	-895	-881	-866	-850	-833	-815	-797
Additional Paid-In Capital	0.6%	1,105	1,098	1,093	1,089	1,083	1,077	1,070	1,063	1,057	1,049	1,035	1,027	1,019	1,013	1,004	995	979	907	894	881	867
Shares Outstanding	0.5%	182	181	180	179	178	178	176	177	174	171	171	170	-	-	-	-	-	-	-	-	-
Minority Interest	-0.3%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	373	-	-	-	906	-	-	-	862	-	-	-	928	-	-	-	771	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	112.9%	1,959	-15,183	-10,489	-8,996	-8,500	-1,756	-2,058	-345	-21,456	-1,222	-6,582	-8,663	-17,455	-8,901	-5,189	-7,919	-19,802	-8,222	-22,217	-12,882	-22,178
Share Based Compensation	19.4%	5,855	4,903	3,979	5,720	5,669	7,255	5,768	5,007	6,426	6,538	5,892	5,808	5,333	4,723	4,846	4,706	3,754	3,700	3,595	3,139	2,878
Cashflow From Investing	-82.4%	1,446	8,216	-275	2,329	-1,646	7,383	-2,066	-5,475	8,622	-40,290	21,729	9,857	21,392	7,602	-5,380	-1,595	-50,185	9,401	10,028	-4,429	13,185
Cashflow From Financing	370.1%	5,561	1,183	7,602	-173	2,061	457	1,084	202	2,449	12,098	4,581	127	17,488	8,287	4,171	10,641	68,684	9,484	13,066	11,804	9,133

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CERS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 14,482	$ 17,384
Selling, general and administrative	19,799	21,551
Total operating expenses	34,281	38,935
Loss from operations	(7,979)	(14,146)
Non-operating expense, net:
Foreign exchange gain (loss)	145	(193)
Interest expense	(2,234)	(1,612)
Other income, net	452	387
Total non-operating expense, net	(1,637)	(1,418)
Loss before income taxes	(9,616)	(15,564)
Provision for income taxes	74	77
Net loss	(9,690)	(15,641)
Net loss attributable to noncontrolling interest	(2)	(22)
Net loss attributable to Cerus Corporation	$ (9,688)	$ (15,619)
Net loss per share attributable to Cerus Corporation
Basic	$ (0.05)	$ (0.09)
Diluted	$ (0.05)	$ (0.09)
Weighted average shares outstanding:
Basic	182,090	178,273
Diluted	182,090	178,273
Product
Revenue	$ 38,365	$ 30,974
Cost of revenue	17,093	13,687
Gross profit	21,272	17,287
Government Contract
Revenue	$ 5,030	$ 7,502

CERS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 20,527	$ 11,647
Short-term investments	51,651	54,205
Accounts receivable, net	22,535	35,500
Current inventories	39,862	39,868
Prepaid and other current assets	3,594	3,221
Total current assets	138,169	144,441
Non-current assets:
Property and equipment, net	8,099	8,640
Operating lease right-of-use assets	10,224	10,713
Goodwill	1,316	1,316
Restricted cash	1,708	1,712
Non-current inventories	17,913	19,501
Other assets	11,707	11,425
Total assets	189,136	197,748
Current liabilities:
Accounts payable	16,616	23,842
Accrued liabilities	16,154	19,225
Debt – current	20,120	20,000
Operating lease liabilities – current	2,188	2,452
Deferred revenue	2,167	2,002
Total current liabilities	57,245	67,521
Non-current liabilities:
Debt – non-current	64,826	59,796
Operating lease liabilities – non-current	13,469	13,751
Other non-current liabilities	3,434	3,236
Total liabilities	138,974	144,304
Commitments and contingencies
Stockholders' equity:
Common stock	185	181
Additional paid-in capital	1,104,605	1,098,353
Accumulated other comprehensive loss	(1,122)	(1,274)
Accumulated deficit	(1,054,298)	(1,044,610)
Total Cerus Corporation stockholders' equity	49,370	52,650
Noncontrolling interest	792	794
Total liabilities and stockholders' equity	$ 189,136	$ 197,748

About Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CEO	Mr. William M. Greenman
WEBSITE	cerus.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	665

Cerus Corp Frequently Asked Questions

What is the ticker symbol for Cerus Corp? What does CERS stand for in stocks?

CERS is the stock ticker symbol of Cerus Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cerus Corp (CERS)?

As of Wed May 08 2024, market cap of Cerus Corp is 347.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERS stock?

You can check CERS's fair value in chart for subscribers.

What is the fair value of CERS stock?

You can check CERS's fair value in chart for subscribers. The fair value of Cerus Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cerus Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CERS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cerus Corp a good stock to buy?

The fair value guage provides a quick view whether CERS is over valued or under valued. Whether Cerus Corp is cheap or expensive depends on the assumptions which impact Cerus Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERS.

What is Cerus Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, CERS's PE ratio (Price to Earnings) is -11.01 and Price to Sales (PS) ratio is 1.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cerus Corp's stock?

In the past 10 years, Cerus Corp has provided -0.071 (multiply by 100 for percentage) rate of return.